Carolina S. Ilkow Ottawa Hospital Research Institute Biography Publications Institution JoVE Articles Carolina S. Ilkow has not added a biography. If you are Carolina S. Ilkow and would like to personalize this page please email our Author Liaison for assistance. Publications Oncolytic Virus Immunotherapy Cancers. Jul, 2021 | Pubmed ID: 34359574 A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion Nanomaterials (Basel, Switzerland). Mar, 2021 | Pubmed ID: 33809836 SARS-CoV-2 S1 NanoBiT: A Nanoluciferase Complementation-based Biosensor to Rapidly Probe SARS-CoV-2 Receptor Recognition Biosensors & Bioelectronics. May, 2021 | Pubmed ID: 33706157 Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction International Journal of Molecular Sciences. Feb, 2021 | Pubmed ID: 33668756 Nanoluciferase Complementation-based Bioreporter Reveals the Importance of N-linked Glycosylation of SARS-CoV-2 S for Viral Entry Molecular Therapy : the Journal of the American Society of Gene Therapy. Jun, 2021 | Pubmed ID: 33578036 Personalized Oncology and BRAF Melanoma: Model Development, Drug Discovery, and Clinical Correlation Journal of Cancer Research and Clinical Oncology. May, 2021 | Pubmed ID: 33555379 Redirecting Oncolytic Viruses: Engineering Opportunists to Take Control of the Tumour Microenvironment Cytokine & Growth Factor Reviews. 12, 2020 | Pubmed ID: 32958389 Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization Membranes. Aug, 2020 | Pubmed ID: 32872641 Hippo Signaling Pathway As a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis Cancers. Jul, 2020 | Pubmed ID: 32722184 Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses Methods in Molecular Biology (Clifton, N.J.). 2020 | Pubmed ID: 31486045 Enhanced Susceptibility of Cancer Cells to Oncolytic Rhabdo-virotherapy by Expression of Nodamura Virus Protein B2 As a Suppressor of RNA Interference Journal for Immunotherapy of Cancer. 06, 2018 | Pubmed ID: 29921327 Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy EBioMedicine. May, 2018 | Pubmed ID: 29724655 A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma Cancer Cell. 08, 2017 | Pubmed ID: 28810141 Complement Inhibition Enables Tumor Delivery of LCMV Glycoprotein Pseudotyped Viruses in the Presence of Antiviral Antibodies Molecular Therapy Oncolytics. 2016 | Pubmed ID: 27909702 VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection Cancer Cell. Aug, 2015 | Pubmed ID: 26212250 Reciprocal Cellular Cross-talk Within the Tumor Microenvironment Promotes Oncolytic Virus Activity Nature Medicine. May, 2015 | Pubmed ID: 25894825 Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques Molecular Therapy : the Journal of the American Society of Gene Therapy. Jun, 2015 | Pubmed ID: 25807289 Maraba MG1 Virus Enhances Natural Killer Cell Function Via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease Molecular Therapy : the Journal of the American Society of Gene Therapy. Jul, 2014 | Pubmed ID: 24695102 Nachweis eines SARS-CoV-2-Rezeptor-bindenden Domänenantikörpers mit einem HiBiT-basierten Bioreporter Reza Rezaei1,2, Abera Surendran1,2, Ragunath Singaravelu1,2, Taylor R. Jamieson1,2, Parisa Taklifi3, Joanna Poutou1,2, Taha Azad1,2, Carolina S. Ilkow1,2 1Ottawa Hospital Research Institute, 2Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 3Department of Biotechnology, University of Tehran JoVE 62488 Immunologie et Infection Nachweis von SARS-CoV-2 neutralisierenden Antikörpern mittels Hochdurchsatz-Fluoreszenzbildgebung von Pseudovirus-Infektionen Taylor R. Jamieson1,2, Joanna Poutou1,2, Ricardo Marius1,2, Xiaohong He1, Reza Rezaei1,2, Taha Azad1,2, Carolina S. Ilkow1,2 1Ottawa Hospital Research Institute, 2Department of Biochemistry, Microbiology and Immunology, University of Ottawa JoVE 62486 Immunologie et Infection
Nachweis eines SARS-CoV-2-Rezeptor-bindenden Domänenantikörpers mit einem HiBiT-basierten Bioreporter Reza Rezaei1,2, Abera Surendran1,2, Ragunath Singaravelu1,2, Taylor R. Jamieson1,2, Parisa Taklifi3, Joanna Poutou1,2, Taha Azad1,2, Carolina S. Ilkow1,2 1Ottawa Hospital Research Institute, 2Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 3Department of Biotechnology, University of Tehran JoVE 62488 Immunologie et Infection
Nachweis von SARS-CoV-2 neutralisierenden Antikörpern mittels Hochdurchsatz-Fluoreszenzbildgebung von Pseudovirus-Infektionen Taylor R. Jamieson1,2, Joanna Poutou1,2, Ricardo Marius1,2, Xiaohong He1, Reza Rezaei1,2, Taha Azad1,2, Carolina S. Ilkow1,2 1Ottawa Hospital Research Institute, 2Department of Biochemistry, Microbiology and Immunology, University of Ottawa JoVE 62486 Immunologie et Infection